The Escherichia phage PGN829.1 was isolated from sewage of a tertiary care referral hospital in North India. It lyses multiple strains of highly drug-resistant uropathogenic E. coli. It belongs to the family Podoviridae. Its genome is closest to that of Escherichia phage Vb_EcoP_PhAPEC7.
database. The GO terms molecular function (MF), cellular component (CC), and biological process (BP) for genes were mapped using the Blast2Go tool (7) . A BLASTn similarity search revealed that the genome of PGN829.1 is closest to Escherichia phage Vb_EcoP_PhAPEC7 (GenBank accession number KF562340), which belongs to a family of noncontractile short-tailed phages known as Podoviridae (8) . Phage PGN829.1 has a genome size of 74.4 kb and a GC content of 42.9%. We conclude that the lytic activity shown by Escherichia phage PGN829.1 against highly drug-resistant UPEC strains may have potential therapeutic value for treating urinary tract infections.
This study was approved by the Institute Ethical Clearance Committee of PGIMER, Chandigarh.
Data availability. The raw sequence reads have been submitted to the NCBI SRA under accession number PRJNA495477, and the draft genome sequence of Escherichia coli phage PGN829.1 has been deposited in NCBI GenBank under accession number MH733496.
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